Have a feature idea you'd love to see implemented?
Let us know!
CNTX Context Therapeutics Inc
Price (delayed)
$1.5
Market cap
$112.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.91
Enterprise value
$27.94M
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a
Highlights
CNTX's EPS is up by 30% year-on-year and by 14% since the previous quarter
Context Therapeutics's net income has plunged by 62% from the previous quarter and by 45% YoY
The quick ratio fell by 43% QoQ
Key stats
What are the main financial stats of CNTX
Market
Valuations
Earnings
Shares outstanding
75M
Market cap
$112.5M
Enterprise value
$27.94M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.34
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$30.15M
EBITDA
-$30.13M
Free cash flow
-$16.88M
Per share
Balance sheet
Liquidity
EPS
-$0.91
Free cash flow per share
-$0.21
Book value per share
$1.12
Revenue per share
$0
TBVPS
$1.07
Total assets
$86.33M
Total liabilities
$2.47M
Debt
$244,360
Equity
$83.86M
Working capital
$83.74M
Debt to equity
0
Current ratio
36.91
Quick ratio
36.36
Net debt/EBITDA
2.81
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-55.8%
Return on equity
-58.8%
Return on invested capital
N/A
Return on capital employed
-35.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CNTX stock price
How has the Context Therapeutics stock price performed over time
Intraday
-7.98%
1 week
-21.05%
1 month
-27.18%
1 year
85.19%
YTD
32.74%
QTD
-23.47%
Financial performance
How have Context Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$32.61M
Net income
-$30.15M
Gross margin
N/A
Net margin
N/A
Context Therapeutics's net income has plunged by 62% from the previous quarter and by 45% YoY
CNTX's operating income has dropped by 62% since the previous quarter and by 48% year-on-year
Growth
What is Context Therapeutics's growth rate over time
Valuation
What is Context Therapeutics stock price valuation
P/E
N/A
P/B
1.34
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CNTX's EPS is up by 30% year-on-year and by 14% since the previous quarter
CNTX's P/B is 26% lower than its last 4 quarters average of 1.8
The equity is down by 17% since the previous quarter
Efficiency
How efficient is Context Therapeutics business performance
CNTX's ROE is up by 25% year-on-year but it is down by 11% since the previous quarter
The ROA has increased by 19% YoY but it has decreased by 15% QoQ
Dividends
What is CNTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CNTX.
Financial health
How did Context Therapeutics financials performed over time
CNTX's total liabilities has soared by 54% since the previous quarter but it is down by 46% year-on-year
The quick ratio fell by 43% QoQ
CNTX's debt is 100% smaller than its equity
The equity is down by 17% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.